Smith Drug Co. v. Actavis (Namenda), No. 15-7488 (S.D.N.Y.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Actavis’ Namenda XR, alleging that Actavis Actavis engaged in an illegal product hop to move the market from Namenda to Namenda XR in order to thwart competition from generic Namenda. (settled for $750 million)
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 10/14/2015
Office
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771